Method for administering an NMDA receptor antagonist to a subject
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/00
A61K-031/17
A01N-047/28
출원번호
US-0751876
(2013-01-28)
등록번호
US-8598233
(2013-12-03)
발명자
/ 주소
Went, Gregory T.
Fultz, Timothy J.
Meyerson, Laurence R.
출원인 / 주소
Adamas Pharmacueticals, Inc.
대리인 / 주소
Scully, Scott, Murphy & Presser, P.C.
인용정보
피인용 횟수 :
15인용 특허 :
88
초록▼
Compositions and methods for administering memantine to a subject are provided. In particular, a solid pharmaceutical composition in a unit dosage form for once daily oral administration is provided. The compositions comprises an extended release formulation of 22.5 mg to 33.75 mg memantine, or a ph
Compositions and methods for administering memantine to a subject are provided. In particular, a solid pharmaceutical composition in a unit dosage form for once daily oral administration is provided. The compositions comprises an extended release formulation of 22.5 mg to 33.75 mg memantine, or a pharmaceutically acceptable salt thereof, wherein administration of a dose of the composition to a human subject provides a mean plasma memantine concentration profile characterized by a change in memantine concentration as a function of time (dC/dT) that is less than 50% of the dC/dT provided by the same quantity of an immediate release form of memantine, determined in a time period between 0 hours to 6 hours after administration of memantine, and wherein dC/dT is measured in a single-dose human PK study. Methods of treating dementia, in particular Alzheimer's diseases, using the compositions are provided.
대표청구항▼
1. A solid pharmaceutical composition in a unit dosage form for once daily oral administration comprising an extended release formulation of 22.5 mg to 33.75 mg memantine, or a pharmaceutically acceptable salt thereof, wherein administration of a dose of the composition to a human subject provides a
1. A solid pharmaceutical composition in a unit dosage form for once daily oral administration comprising an extended release formulation of 22.5 mg to 33.75 mg memantine, or a pharmaceutically acceptable salt thereof, wherein administration of a dose of the composition to a human subject provides a mean plasma memantine concentration profile characterized by a change in memantine concentration as a function of time (dC/dT) that is less than 50% of the dC/dT provided by the same quantity of an immediate release form of memantine, determined in a time period between 0 hours to 6 hours after administration of memantine, and wherein dC/dT is measured in a single-dose human PK study. 2. The composition of claim 1, comprising 22.5 mg to 30 mg memantine or a pharmaceutically acceptable salt thereof. 3. The composition of claim 1, comprising 28 mg memantine or a pharmaceutically acceptable salt thereof. 4. The composition of claim 1, wherein administration of a dose of the composition to a human subject provides a mean plasma memantine concentration profile characterized by dC/dT that is 2.1 ng/ml/hr or less, determined in a time period of 0 hours to 4 hours after administration of memantine, and wherein dC/dT is measured in a single-dose human PK study. 5. The composition of claim 4, wherein the dC/dT of 2.1 ng/ml/hr or less is determined in a time period of 2 hours to 4 hours after administration of memantine. 6. The composition of claim 2, wherein administration of a dose of the composition to a human subject provides a mean plasma memantine concentration profile characterized by dC/dT that is 2.1 ng/ml/hr or less, determined in a time period of 0 hours to 4 hours after administration of memantine, and wherein dC/dT is measured in a single-dose human PK study. 7. The composition of claim 6, wherein the dC/dT of 2.1 ng/ml/hr or less is determined in a time period of 2 hours to 4 hours after administration of memantine. 8. The composition of claim 3, wherein administration of a dose of the composition to a human subject provides a mean plasma memantine concentration profile characterized by dC/dT that is 2.1 ng/ml/hr or less, determined in a time period of 0 hours to 4 hours after administration of memantine, and wherein dC/dT is measured in a single-dose human PK study. 9. The composition of claim 8, wherein the dC/dT of 2.1 ng/ml/hr or less is determined in a time period of 2 hours to 4 hours after administration of memantine. 10. A solid pharmaceutical composition in an unit dosage form consisting essentially of 22.5 to 37.5 mg memantine or a pharmaceutically acceptable salt thereof provided in an extended release dosage form, wherein administration of the dosage form provides a mean plasma memantine concentration profile characterized by a change in memantine concentration of memantine as a function of time (dC/dT) that is less than about 50% of the dC/dT provided by the same quantity of an immediate release form of memantine, determined in a time period between 0 hours to 6 hours of administration of memantine, and wherein dC/dT is measured in a single-dose human PK study. 11. The composition of claim 10, comprising 22.5 mg to 30 mg memantine or a pharmaceutically acceptable salt thereof. 12. The composition of claim 10, comprising 28 mg memantine or a pharmaceutically acceptable salt thereof. 13. The composition of claim 10, wherein administration of a dose of the composition to a human subject provides a mean plasma memantine concentration profile characterized by dC/dT that is 2.1 ng/ml/hr or less, determined in a time period of 0 hours to 4 hours after administration of memantine, and wherein dC/dT is measured in a single-dose human PK study. 14. The composition of claim 13, wherein the dC/dT of 2.1 ng/ml/hr or less is determined in a time period of 2 hours to 4 hours after administration of memantine. 15. The composition of claim 11, wherein administration of a dose of the composition to a human subject provides a mean plasma memantine concentration profile characterized by dC/dT that is 2.1 ng/ml/hr or less, determined in a time period of 0 hours to 4 hours after administration of memantine, and wherein dC/dT is measured in a single-dose human PK study. 16. The composition of claim 15, wherein the dC/dT of 2.1 ng/ml/hr or less is determined in a time period of 2 hours to 4 hours after administration of memantine. 17. The composition of claim 12, wherein administration of a dose of the composition to a human subject provides a mean plasma memantine concentration profile characterized by dC/dT that is 2.1 ng/ml/hr or less, determined in a time period of 0 hours to 4 hours after administration of memantine, and wherein dC/dT is measured in a single-dose human PK study. 18. The composition of claim 17, wherein the dC/dT of 2.1 ng/ml/hr or less is determined in a time period of 2 hours to 4 hours after administration of memantine.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (88)
Kelleher Judith A. ; Maples Kirk R. ; Dykman Alina ; Zhang Yong-Kang ; Wilcox Allan L. ; Levell Julian, .alpha.-aryl-N-alkylnitrones and pharmaceutical compositions containing the same.
Bormann Joachim (Frankfurt DEX) Gold Markus R. (Nauheim DEX) Schatton Wolfgang (Eschborn DEX), Adamantane derivatives in the prevention and treatment of cerebral ischemia.
Rudnic Edward M. ; Belendiuk George W. ; McCarty John ; Wassink Sandra ; Couch Richard A., Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine.
Guittard George V. (Cupertino CA) Wong Patrick S. L. (Palo Alto CA) Kuczynski Anthony L. (Mountain View CA) Kidney David J. (Palo Alto CA), Antiviral therapy.
Nickel Bernd (Mhltal DEX) Lobisch Michael (Ober-Ramstadt DEX) Szelenyi Istvan (Schwaig DEX) Engel Jrgen (Alzenau DEX) Emig Peter (Niederdorfelden DEX) Pergande Gabriela (Offenbach DEX), Combination medication containing flupirtin and morphine for the treatment of pain and the prevention of morphine depend.
Cordi Alex A. (St. Louis MO) Jans Michel R. (Brussels BEX), Composition containing D-cycloserine and D-alanine for memory and learning enhancement or treatment of a cognitive or ps.
Wong, Patrick S. L.; Dong, Liang C.; Wan, Jiansheng, Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings.
Cordi Alex A. (St. Louis MO) Handelmann Gail E. (Chesterfield MO) Monahan Joseph B. (Black Jack MO), D-cycloserine and its prodrugs as cognitive enhancers.
Prausnitz, Mark R.; Allen, Mark G.; Henry, Sebastien; McAllister, Devin V.; Ackley, Donald E.; Jackson, Thomas, Devices and methods for enhanced microneedle penetration of biological barriers.
Edgren David E. (El Granada) Carpenter Howard A. (Palo Alto) Bhatti Gurdish K. (Fremont) Ayer Atul D. (Palo Alto CA), Dosage form for treating central nervous system disorders.
Edgren David E. (El Granada CA) Carpenter Howard A. (Palo Alto CA) Bhatti Gurdish K. (Fremont CA) Ayer Atul D. (Palo Alto CA), Dosage form indicated for the management of abnormal posture, tremor and involuntary movement.
Edgren David E. (El Granada) Carpenter Howard A. (Palo Alto) Bhatti Gurdish K. (Fremont) Ayer Atul D. (Palo Alto CA), Dosage form indicated for the management of abnormal posture, tremor and involuntary movement.
Nrnberg Eberhard (Uttenreuth/Welher DEX) Seiller Erhard (Nidderau DEX) Ritsert Stefan (Eberbach DEX), Memantine-containing solid pharmaceutical dosage forms having an extended two-stage release profile and production there.
Lam, Andrew C.; Shivanand, Padmaja; Ayer, Atul D.; Weyers, Richard G.; Gupta, Suneel K.; Guinta, Diane R.; Christopher, Carol A.; Saks, Samuel R.; Hamel, Lawrence G.; Wright, Jeri D.; Hatamkhany, Zah, Methods and devices for providing prolonged drug therapy.
Chen, Guohua; Lautenbach, Scott D.; Dionne, Keith E.; Jordan, Scott D.; Berry, Steve A.; Rodenberger, Craig I.; Ayer, Rupal, Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems.
Lobisch Michael (Ober-Ramstadt DEX) Venhaus Ralph (Heppenheim DEX) Nickel Bernd (Mhltal DEX) Szelenyi Istvan (Schwaig DEX) Engel Jrgen (Alzenau DEX) Emig Peter (Niederdorfelden DEX), Pharmaceutical composition comprising flupirtine and its use to combat muscular tension.
Buxton Ian R. (Cambridge GBX) Critchley Helen (Cambridge GBX) Leslie Stewart T. (Cambridge GBX) Prater Derek A. (Cambridge GBX) Miller Ronald B. (Basle CHX) Malkowska Sandra T. A. (Cambridge GBX), Pharmaceutical spheroid formulation.
Rudnic Edward M. ; Burnside Beth A. ; Flanner Henry H. ; Wassink Sandra E. ; Couch Richard A. ; Pinkett Jill E., Soluble form osmotic dose delivery system.
Peery, John R.; Dionne, Keith E.; Eckenhoff, James B.; Landrau, Felix A.; Lautenbach, Scott D.; Magruder, Judy A.; Wright, Jeremy C., Sustained delivery of an active agent using an implantable system.
Hanns Ludwig DE; Detlef Dietrich DE; Hinderk M. Emrich DE; Liv Bode DE, USE OF ADAMANTANE AMINES OR STRUCTURALLY SIMILAR COMPOUNDS FOR COMBATING BORNA DISEASE VIRUS AND FOR THE PREVENTION AND TREATMENT OF AFFECTIVE DISEASES AND OTHER DISORDERS ASSOCIATED WITH BDV INFECTI.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.